FrancophonIA/ELRC3.0 huggingface dataset:
English: The vaccine can be used together with Tetanus-Serum for treatment of injured horses that have not been immunised against tetanus.
Slovenian: Cepivo lahko uporabljamo hkrati s Tetanus-Serumom za zdravljenje poškodovanih konj, ki niso bili cepljeni proti tetanusu.
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental self-injection, seek medical advice immediately and show this package insert or the label to the physician.
Slovenian: Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Če vam je bil ta izdelek nenamerno injiciran, se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Slovenian: IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA PROIZVODNJO ZDRAVILA, ODGOVORNEGA ZA SPROŠČANJE SERIJ, ČE STA RAZLIČNA
English: A clear opalescent suspension.
Slovenian: Bistra opalescentna suspenzija
English: A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Slovenian: A. IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
English: Pharmacotherapeutic group: Inactivated bacterial vaccine.
Slovenian: Za vzbujanje aktivne imunosti proti tetanusu Farmakoterapevtska skupina: inaktivirano bakterijsko cepivo
English: V3
Slovenian: C3
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label.
Slovenian: Tega zdravila za uporabo v veterinarski mediini ne smete uporabljati po datumu izteka roka uporabnosti,
English: Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig serum in the Ph. Eur.
Slovenian: flokulacijski ekvivalenti; ustreza ≥ 30 i.e./ml seruma budre v Ph. Eur.
English: Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Tetanus Serum from Intervet.
Slovenian: Na voljo so podatki o varnosti in učinkovitosti, ki kažejo, da lahko cepivo dajemo isti dan, toda ne pomešano z Intervetovim Tetanus-Serumom.
English: In very rare cases, fever, sometimes accompanied by lethargy and inappetence, may occur for 1 day, and up to 3 days in exceptional circumstances.
Slovenian: V zelo redkih primerih se lahko za 1 dan, izjemoma za do 3 dni pojavi vročina, ki jo včasih spremlja letargija in inapetenca.
English: 1 ml suspension in type I glass pre-filled syringe, containing a plunger with a halogenobutyl end and closed with a halogenobutyl stopper.
Slovenian: 1 ml suspenzije v napolnjeni brizgi iz stekla tipa I, v kateri je bat z nastavkom iz halogenobutila in je zaprta z zamaškom iz halogenobutilne gume.
English: 1 ml suspension in type I glass vial closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.
Slovenian: 1 ml suspenzije v viali, steklo tipa I, zaprti z zamaškom iz halogenobutilne gume in zatesnjeni z aluminijasto zaporko.
English: PACKAGE LEAFLET FOR Equilis Te suspension for injection for horses
Slovenian: Equilis Te, suspenzija za injiciranje za konje
English: 2 weeks after the primary vaccination course
Slovenian: 2 tedna po osnovnem cepljenju
English: Intervet International B.V. NL-5831 AN Boxmeer
Slovenian: NL-5831 AN Boxmeer
English: Incompatibilities: Do not mix with any other veterinary medicinal product.
Slovenian: 6.2 Inkompatibilnosti Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
Slovenian: Vsak odmerku po 1 ml vsebuje:
English: 17 months after the primary vaccination course
Slovenian: 17 mesecev po osnovnem cepljenju
English: A diffuse hard or soft swelling (max. diameter 5 cm) may rarely occur at the injection site, regressing within 2 days.
Slovenian: Neostro omejena trda ali mehka oteklina (s premerom največ 5 cm) se lahko pojavi na mestu dajanja, ki mine v 2 dneh.
English: Concurrent use of Equilis Te and Tetanus-Serum from Intervet may reduce active immunity against tetanus compared to horses vaccinated with Equilis Te in the absence of tetanus antitoxin serum.
Slovenian: Sočasna uporaba Equilisa Te in Intervetovega Tetanus-Seruma lahko zmanjša aktivno imunost proti tetanusu v primerjavi s konji, cepljenimi z Equilisom Te, ki niso prejeli seruma z antitoksinom tetanusa.
English: Cardboard box with 10 glass vials.
Slovenian: Škatla z 10 steklenimi vialami.
English: Suspension for injection.
Slovenian: FARMACEVTSKA OBLIKA Suspenzija za injiciranje.
English: Active immunisation of horses from 6 months of age against tetanus to prevent mortality.
Slovenian: INDIKACIJA(E) Aktivna imunizacija konj po šestem mesecu starosti proti tetanusu za preprečevanje umrljivosti
English: Onset of immunity:
Slovenian: Razvoj imunosti:
English: Following the administration of a double dose of vaccine, no side effects other than those described under section 4.6 have been observed except for some depression at the day of vaccination.
Slovenian: 4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno) Dvojni odmerek cepiva ni povzročil neželenih učinkov, ki bi se razlikovali od tistih, opisanih v poglavju 4.6, razen blage depresivnosti na dan cepljenja.
English: Phosphatidylcholine
Slovenian: holesterol, fosfatidil holin
English: EXP {month/year}
Slovenian: DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP {mesec(leto}
English: Equilis Te [a clear pictogram of a horse]
Slovenian: IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Equilis Te [jasen piktogram konja]
English: Name and address of the manufacturers of the biological active substance GSK Vaccines GmbH
Slovenian: Ime in naslov izdelovalcev biološke zdravilne učinkovine
English: THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN" Keep out of the sight and reach of children.
Slovenian: BESEDILO “ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM ” Zdravilo shranjujte nedosegljivo otrokom.
English: Cardboard box with 10 pre-filled syringes with needles.
Slovenian: Škatla z 10 napolnjenimi brizgami z iglami.
English: Name and address of the manufacturer responsible for batch release
Slovenian: Ime in naslov izdelovalca zdravila, odgovornega za sprostitev serije Intervet International BV
English: EU/2/05/055/001 EU/2/05/055/002
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/05/055/001-002
English: Emil-von-Behring-Str. 76 35 041 Marburg Germany
Slovenian: GSK Vaccines GmbH Emil-von-Behring-Str. 76
English: Phosphate buffer Chloride buffer
Slovenian: Laktoza, fosfatni pufer, kloridni pufer, sledi formaldehida,
English: Lot {number}
Slovenian: (otrdelost).
English: Cardboard box with 10 pre-filled syringes with needles
Slovenian: Škatla z 10 vialami Škatla z 10 napolnjenimi brizgami z iglami
English: MARKETING AUTHORISATION NUMBER(S)
Slovenian: NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN ZAOSTANKOV ZDRAVILA ( MRL)
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 1 ml vial and 1 ml pre-filled syringe
Slovenian: OVOJNINAH Viala z 1 ml in napolnjena brizga
English: 125 µg Phosphatidylcholine 62.5 µg
Slovenian: 62,5 µg
English: Pack size blister (PVC/alu) 90 x 1 tablets (unit dose)
Slovenian: 90 x 1 filmsko obložena tableta (posamezni odmerek)
English: This summary was last updated in 03-2010.
Slovenian: Povzetek je bil nazadnje posodobljen 03-2010.
English: The European Commission granted a marketing authorisation valid throughout the EU for Avandamet to SmithKline Beecham Ltd. on 20 October 2003.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Avandamet, veljavno po vsej Evropski uniji, odobrila družbi SmithKline Beecham Ltd. dne 20. oktobra 2003.
English: What benefit has Avandamet shown during the studies?
Slovenian: Kakšne koristi je zdravilo Avandamet izkazalo med študijami?
English: After five years, the marketing authorisation was
Slovenian: Po petih letih je bilo dovoljenje za promet z zdravilom podaljšano za nadaljnjih pet let.
English: For more information about treatment with Avandamet, read the Package Leaflet (also part of the EPAR).
Slovenian: Za več informacij o zdravljenju z zdravilom Avandamet preberite navodilo za uporabo (ki je prav tako del EPAR).
English: It must not be used in patients who have heart failure (an inability of the heart to pump enough blood around the body), an ‘acute coronary syndrome' such as unstable angina (a severe type of chest pain that changes in intensity) or certain types of heart attack, diseases that could affect the oxygen supply to the tissues (such as lung or heart problems, a recent heart attack or shock), problems with their liver or kidneys, acute alcohol intoxication (excessive alcohol consumption), alcoholism, or complications of diabetes (diabetic ketoacidosis or diabetic coma).
Slovenian: Uporabljati ga ne smejo bolniki s srčnim popuščanjem (nezmožnostjo srca, da poganja dovolj krvi po telesu), „akutnim koronarnim sindromom“, kot so nestabilna angina pektoris (huda vrsta bolečine v prsih, katere jakost se naglo spreminja) ali določene oblike srčnega napada, boleznimi, ki bi lahko vplivale na oskrbo tkiv s kisikom (kot so pljučne ali srčne bolezni, nedavni srčni napad ali šok), težavami z jetri in ledvicami, hudo zastrupitvijo z alkoholom (pretirano pitje alkohola), alkoholiki ali bolniki z zapleti sladkorne bolezni (diabetično ketoacidozo ali diabetično komo).
English: What is the risk associated with Avandamet?
Slovenian: Kakšna tveganja so povezana z zdravilom Avandamet?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z zdravilom in priporočila glede pogojev uporabe zdravila Avandamet.
English: This document is a summary of the European Public Assessment Report (EPAR) for Avandamet.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Avandamet.
English: The doses of Avandamet may need to be adjusted when given with certain other medicines such as gemfibrozil or rifampicin.
Slovenian: Odmerke zdravila Avandamet bo morda treba prilagoditi, kadar ga uporabljamo z nekaterimi drugimi zdravili, na primer gemfibrozilom ali rifampicinom.
English: • metformin works mainly by inhibiting glucose production and reducing its absorption in the gut.
Slovenian: • metformin pa učinkuje predvsem tako, da zavira nastajanje glukoze in zmanjšuje njeno absorpcijo v črevesju.
English: The most common side effect with Avandamet (seen in more than 1 patient in 10) is gastrointestinal symptoms (such as feeling sick, vomiting, diarrhoea, stomach ache and loss of appetite).
Slovenian: Najpogostejši neželeni učinki zdravila Avandamet (opaženi pri več kot 1 bolniku od 10) so gastrointestinalni simptomi (kot so slabost, bruhanje, driska, bolečina v trebuhu in izguba teka).
English: The studies of Avandia taken with metformin as separate tablets were used to support the use of Avandamet.
Slovenian: Študije zdravila Avandia, uporabljenega skupaj z metforminom v obliki ločenih tablet, so bile uporabljene v podporo uporabi zdravila Avandamet.
English: Avandamet contains two active substances, which have different modes of action:
Slovenian: Zdravilo Avandamet vsebuje dve zdravilni učinkovini, ki imata različen način delovanja:
English: Taking Avandamet with or just after food may reduce any stomach problems caused by metformin.
Slovenian: Jemanje zdravila Avandamet sočasno s hrano ali neposredno po obroku lahko ublaži želodčne težave, ki jih povzroča metformin.
English: It is available as tablets (yellow: 1 mg rosiglitazone and 500 mg metformin hydrochloride, and 2 mg rosiglitazone and 1,000 mg metformin hydrochloride; pale pink: 2 mg rosiglitazone and 500 mg metformin hydrochloride; pink: 4 mg rosiglitazone and 1,000 mg metformin
Slovenian: Na voljo je v obliki tablet (rumenih: 1 mg rosiglitazona in 500 mg metforminijevega klorida in 2 mg rosiglitazona in 1000 mg metforminijevega klorida; bledo rožnatih: 2 mg rosiglitazona in 500 mg metforminijevega klorida, rožnatih: 4 mg rosiglitazona in 1000 mg metforminijevega klorida).
English: Avandamet is used in patients who have type 2 diabetes, particularly those who are overweight.
Slovenian: Zdravilo Avandamet se uporablja pri bolnikih, ki imajo sladkorno bolezen tipa 2, še zlasti pri bolnikih s čezmerno telesno maso.
English: Avandamet should not be used in people who may be hypersensitive (allergic) to rosiglitazone, metformin or any of the other ingredients.
Slovenian: Zdravila Avandamet ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) rosiglitazon, metformin ali katero koli drugo sestavino zdravila.
English: Rosiglitazone has been authorised in the European Union (EU) as Avandia since 2000, to be used with metformin in type 2 diabetes patients who are not satisfactorily controlled on metformin alone.
Slovenian: Rosiglitazon je v Evropski uniji (EU) odobren od leta 2000 pod imenom Avandia za uporabo skupaj z metforminom pri bolnikih s sladkorno boleznijo tipa 2, pri katerih samo z metforminom ni mogoče doseči zadovoljivega nadzora.
English: Avandamet is a medicine that contains two active substances, rosiglitazone and metformin hydrochloride.
Slovenian: Avandamet je zdravilo, ki vsebuje dve zdravilni učinkovini, rosiglitazon in metforminijev klorid.
English: rosiglitazone and metformin hydrochloride
Slovenian: Avandamet rosiglitazon in metforminijev klorid
English: It is given in two divided doses, either as two 1-mg/500-mg tablets or one
Slovenian: Daje se v obliki dveh ločenih odmerkov, bodisi kot dve tableti 1 mg/500 mg bodisi kot ena tableta 2 mg/1000 mg.
English: The recommended starting dose of Avandamet is 4 mg rosiglitazone and 2,000 mg metformin hydrochloride a day.
Slovenian: Priporočeni začetni odmerek zdravila Avandament je 4 mg rosiglitazona in 2000 mg metforminijevega klorida na dan.
English: The rosiglitazone dose may need to be increased to 8 mg a day after eight weeks if better blood glucose control is needed, but this should be done with caution in patients who are also taking a sulphonylurea, due to the risk of fluid retention.
Slovenian: Če je potrebno močnejše uravnavanje koncentracije glukoze v krvi, se lahko ta odmerek po osmih tednih poveča na 8 mg rosiglitazona na dan, vendar pa je pri bolnikih, ki hkrati jemljejo tudi sulfonilsečnino, potrebna previdnost zaradi tveganja za zastajanje tekočine.
English: The CHMP decided that Avandamet's benefits are greater than its risks and recommended that it be
Slovenian: CHMP je zaključil, da so koristi zdravila Avandamet večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: Another study was also carried out comparing the effects of adding either rosiglitazone or placebo (a dummy treatment) to metformin.
Slovenian: Izvedena je bila tudi druga študija, v okviru katere so primerjali učinke dodajanja rosiglitazona ali placeba (zdravila brez zdravilne učinkovine) metforminu.
English: In triple therapy, one study looked at the effect of adding rosiglitazone to a sulphonylurea (glibenclamide) and metformin in 1,202 patients whose blood glucose was not being controlled
Slovenian: V eni študiji zdravljenja s tremi zdravili hkrati so proučevali učinek dodajanja rosiglitazona sulfonilsečnini (glibenklamidu) in metforminu pri 1202 bolnikih, pri katerih glukoza v krvi ni bila zadostno uravnana.
English: For the full list of all side effects reported with Avandamet, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Avandamet, glejte navodilo za uporabo.
English: If the patient is already using triple therapy, then Avandamet is given to provide the same doses of rosiglitazone and metformin as before.
Slovenian: Če je pri bolniku že bilo uvedeno zdravljenje s tremi zdravili hkrati, se Avandamet predpiše tako, da zagotavlja enake odmerke rosiglitazona in metformina, kot jih je bolnik prejemal dotlej.
English: As a result of the action of both active substances, the blood glucose is reduced and this helps to
Slovenian: Kot posledica delovanja obeh zdravilnih učinkovin se koncentracija glukoze v krvi zniža, to pa prispeva k nadzoru sladkorne bolezni tipa 2.
English: Avandamet was more effective than metformin alone and than placebo in reducing HbA1c.
Slovenian: Zdravilo Avandamet je bilo pri zniževanju koncentracije HbA1c učinkovitejše od metformina kot samostojnega zdravila ter od placeba.
English: Adding rosiglitazone to treatment with metformin and a sulphonylurea brought about a small but significant
Slovenian: Dodajanje rosiglitazona zdravljenju z metforminom in sulfonilsečnino je pripeljalo do majhnega, vendar pomembnega dodatnega znižanja ravni HbA1c.
English: The full EPAR for Avandamet can be found here.
Slovenian: Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Avandamet je na voljo tukaj.
English: Avandamet can also be used with a sulphonylurea (another type of antidiabetes medicine) in patients who are not satisfactorily controlled on metformin and a sulphonylurea at their maximum possible
Slovenian: Avandamet se lahko uporablja tudi skupaj s sulfonilsečnino (drugo vrsto zdravila proti sladkorni bolezni) pri bolnikih, pri katerih z metforminom in sulfonilsečnino v njunih najvišjih dovoljenih odmerkih bolezen ni zadostno nadzorovana (zdravljenje s tremi zdravili hkrati).
English: Avandamet is used in patients who are not satisfactorily controlled on metformin (an antidiabetes medicine) used on its own and at the maximum possible dose (‘dual therapy').
Slovenian: Zdravilo Avandamet se uporablja pri bolnikih, pri katerih z uporabo samo metformina (zdravila proti sladkorni bolezni), tudi v največjem možnem odmerku, ni mogoče doseči zadovoljivega nadzora.
English: In triple therapy, when starting treatment in patients who are already taking metformin and a sulphonylurea, Avandamet is given so that the patient receives 4 mg of rosiglitazone a day, and the same dose of metformin as before.
Slovenian: Največji priporočeni dnevni odmerek je 8 mg/2000 mg. Odmerek rosiglitazona je mogoče dodati metforminu in ga prilagoditi še pred prehodom na zdravilo Avandamet Ko začnemo zdravljenje s tremi zdravili hkrati pri bolnikih, ki že jemljejo metformin in sulfonilsečnino, se Avandamet daje tako, da bolnik prejme 4 mg rosiglitazona na dan in enak odmerek metformina, kot ga je dobival dotlej.
English: Invented Name Strength Pharmaceutical Form Route of Administration
Slovenian: Farmacevtska oblika Pot uporabe
English: Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states
Slovenian: Priloga I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH
English: Strength
Slovenian: ČLANICAH
English: Marketing authorisation holder
Slovenian: Imetnik dovoljenja za promet z zdravilom Izmišljeno ime
English: The full EPAR and risk management plan summary for Duaklir Genuair can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Duaklir Genuair sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Duaklir Genuair on 19 November 2014.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Duaklir Genuair, veljavno po vsej Evropski uniji, izdala dne 19. novembra 2014.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Duaklir Genuair's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Duaklir Genuair večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: What measures are being taken to ensure the safe and effective use of Duaklir Genuair?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Duaklir Genuair?
English: Duaklir Genuair is used for maintenance (regular) treatment.
Slovenian: Zdravilo Duaklir Genuair se uporablja za vzdrževalno (redno) zdravljenje.
English: This is a summary of the European public assessment report (EPAR) for Duaklir Genuair.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Duaklir Genuair.
English: Regarding safety, the number of side effects reported with Duaklir Genuair was low and did not raise any major safety concern.
Slovenian: Kar zadeva varnost, je bilo število neželenih učinkov, o katerih so poročali pri uporabi zdravila Duaklir Genuair, majhno in ni vzbudilo večjih pomislekov glede varnosti.
English: Other information about Duaklir Genuair
Slovenian: Druge informacije o zdravilu Duaklir Genuair
English: In addition, as long-acting muscarinic antagonists may have an effect on the heart and blood vessels, the company that markets Duaklir Genuair will provide the results of studies to further evaluate the cardiovascular safety of the medicine.
Slovenian: Poleg tega bo glede na to, da lahko dolgodelujoči muskarinski antagonisti vplivajo na srce in krvne žile, družba, ki trži zdravilo Duaklir Genuair, predložila rezultate študij, namenjenih podrobnejši oceni varnosti zdravila za srce in ožilje.
English: Duaklir Genuair is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Slovenian: Duaklir Genuair je zdravilo, ki se uporablja za lajšanje simptomov kronične obstruktivne pljučne bolezni (KOPB) pri odraslih.
English: A risk management plan has been developed to ensure that Duaklir Genuair is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Duaklir Genuair je bil pripravljen načrt obvladovanja tveganj.
English: Why is Duaklir Genuair approved?
Slovenian: Zakaj je bilo zdravilo Duaklir Genuair odobreno?
English: The recommended dose of Duaklir Genuair is one inhalation twice a day.
Slovenian: Priporočeni odmerek zdravila Duaklir Genuair je en vdih dvakrat dnevno.
English: It is not intended to provide practical advice on how to use Duaklir Genuair.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: What benefits of Duaklir Genuair have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Duaklir Genuair izkazalo v študijah?
English: Duaklir Genuair aclidinium bromide / formoterol fumarate dihydrate
Slovenian: Duaklir Genuair aklidinijev bromid/formoterolijev fumarat dihidrat
English: What are the risks associated with Duaklir Genuair?
Slovenian: Kakšna tveganja so povezana z zdravilom Duaklir Genuair?
English: For more information about treatment with Duaklir Genuair, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Duaklir Genuair preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: What is Duaklir Genuair and what is it used for?
Slovenian: Kaj je zdravilo Duaklir Genuair in za kaj se uporablja?
English: Results showed that, after six months of treatment, the increase in FEV1 (measured one hour after an inhalation) was 293 milliliters (ml) more with Duaklir Genuair than with placebo and 118 ml more with Duaklir Genuair than with aclidinium alone.
Slovenian: Rezultati so pokazali, da se je po šestih mesecih zdravljenja volumen FEV1 (izmerjen eno uro po vdihavanju) pri uporabi zdravila Duaklir Genuair povečal za 293 mililitrov (ml) več kot pri uporabi placeba in za 118 ml več kot pri uporabi aklidinija kot samostojnega zdravila.